三生國健藥業(yè)（上海）股份有限公司（簡稱“三生國健”）：
????2002年，中國中信集團與蘭生國健藥業(yè)發(fā)起投資成立生物醫(yī)藥高新技術企業(yè)——上海中信國健藥業(yè)股份有限公司；2015年，香港上市公司三生制藥進行股權投資成為該公司最大股東，并將公司更名為三生國健藥業(yè)（上海）股份有限公司。十幾年來，三生國健始終專注于抗體藥物研發(fā)、中試和產業(yè)化，已成功建立了擁有自主知識產權的抗體藥物研發(fā)平臺，掌握研發(fā)與產業(yè)化的核心技術并參與多個抗體藥物質控國家標準的建立。公司擁有通過國家食藥監(jiān)總局（CFDA）GMP認證的3條750升、2條3000升抗體藥物生產線；符合歐盟標準的6條5000升抗體藥物生產線于2015年完成建設并成功試生產，生產規(guī)模和質控水平位居國內行業(yè)領先地位。三生國健提供覆蓋自身免疫、腫瘤、抗器官移植排斥反應等重大疾病領域的靶向藥物，具備持續(xù)開發(fā)新藥的能力，現已發(fā)展成為國內抗體制藥領域的領軍企業(yè)。簡介（英文）：Sunshine?Guojian?Pharmaceutical?(Shanghai)?Co.,?Ltd.?(Sunshine?Guojian),whose?predecessor?is?Shanghai?CP?Guojian?Pharmaceutical?Co.,?Ltd.?jointly?invested?in?2002?as?a?biomedical?high-tech?enterprise?by?China?CITIC?Group?and?the?Lansheng?Guojian?Pharmaceutical?Co.,?Ltd.,?is?established?in?2015?and?integrated?into?the?Sunshine?Pharmaceutical?Group,?a?Hong?Kong?listed?company,?upon?equity?investment.?Over?the?past?decade,?Sunshine?Guojian?has?committed?to?the?R&D,?pilot?scale?development?and?industrialization?of?antibody?drugs.?The?company?has?built?up?a?self-owned?antibody?drug?discovery?platform?with?core?technologies?and?know-hows,?as?well?as?led?or?participated?in?drafting?of?national?standards?in?antibody?drug?quality?control.?Sunshine?Guojian’s?antibody?drug?production?lines?(3*750L?and?2*3000L)?has?been?granted?the?GMP?certificate?by?CFDA?and?its?new?production?lines?(6*5000L)?by?EU?standards?were?completed?construction?and?realized?successful?trial?production?in?2015,?leading?in?production?scale?and?quality?control?in?the?domestic?industry.?As?a?leading?player?in?the?field?of?domestic?pharmaceutical?antibody,?the?company?provides?targeted?drugs?for?autoimmune?diseases,?cancer,?organ?transplantation?immunosuppression?treatment,?with?a?sustainable?capability?of?drug?innovation?and?development.現由于公司發(fā)展需要，誠聘具有創(chuàng)新精神和成就事業(yè)理想的優(yōu)秀人才加盟。請符合條件的應聘者將中英文簡歷等信息發(fā)送E-mail至：hr@gj.3sbio.com?（請在郵件題目上注明應聘職位等信息）
